Calcium Channel

Ca2+ channels; Ca channels

Calcium channel is an ion channel which displays selective permeability to calcium ions. It is sometimes synonymous as voltage-dependent calcium channel, although there are also ligand-gated calcium channels. Voltage-gated calcium (CaV) channels catalyse rapid, highly selective influx of Ca^{2+} into cells despite a 70-fold higher extracellular concentration of Na^{+}. Some calcium channel blockers have the added benefit of slowing your heart rate, which can further reduce blood pressure, relieve chest pain (angina) and control an irregular heartbeat.

(+)-Kavain

Cat. No.: HY-B1671

(+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na^+ and Ca^{2+} channels.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

(-)-Denudatin B

(Denudatin B)

Cat. No.: HY-N3729

(-)-Denudatin B is an antiplatelet agent. (-)-Denudatin B relaxed vascular smooth muscle by inhibiting the Ca2+ influx through voltage-gated and receptor-operated **Ca2+ channels**. And (-)-Denudatin B has nonspecific antiplatelet action.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(2R/S)-6-PNG

(6-Prenylnaringenin)

Cat. No.: HY-115681

(2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible **$Ca_v3.2$ T-type Ca^{2+} channels (T-channels)** blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice.



Purity: ≥99.0%
Clinical Data: Phase 1
Size: 5 mg

(R)-(+)-Bay-K-8644

Cat. No.: HY-15125

(R)-(+)-Bay-K-8644 is a **calcium channel** inhibitor. (R)-(+)-Bay-K-8644 inhibits Ba^{2+} currents (I_{Ba}) (**IC_{50}**=975 nM).



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(R)-(-)-Felodipine-d5

Cat. No.: HY-132670S

(R)-(-)-Felodipine-d5 is the deuterium labeled (R)-(-)-Felodipine. (R)-(-)-Felodipine is the S enantiomer of Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective **calcium channel** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

(R)-Lercanidipine hydrochloride

Cat. No.: HY-B0612D

(R)-Lercanidipine hydrochloride is the R-enantiomer of Lercanidipine. (R)-lercanidipine hydrochloride is a calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Lercanidipine-d3 hydrochloride

Cat. No.: HY-B0612DS

(R)-lercanidipine D3 (hydrochloride) is a deuterium labeled (R)-Lercanidipine hydrochloride. (R)-Lercanidipine D3 (hydrochloride), the R-enantiomer of Lercanidipine, is a **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-MEM 1003

Cat. No.: HY-121604

(Rac)-MEM 1003 is the racemate of MEM 1003. MEM 1003, a dihydropyridine compound, is a potent L-type **Ca^{2+}** channel antagonist and has the potential for Alzheimer's disease research.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(S)-(-)-Bay-K-8644

Cat. No.: HY-15124

(S)-(-)-Bay-K-8644 is an agonist of L-type **Ca^{2+} channel**. (S)-(-)-Bay-K-8644 activates Ba^{2+} currents (I_{Ba}) (**EC_{50}**=32 nM).



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

(S)-Lercanidipine hydrochloride

Cat. No.: HY-B0612E

(S)-Lercanidipine hydrochloride is the S-enantiomer of Lercanidipine hydrochloride. (S)-lercanidipine hydrochloride is a potent calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

(S)-Verapamil D7 hydrochloride

((S)-(-)-Verapamil D7 hydrochloride) Cat. No.: HY-135336AS

(S)-Verapamil D7 hydrochloride ((S)-(-)-Verapamil D7 hydrochloride) is a deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

(S)-Verapamil hydrochloride

((S)-(-)-Verapamil hydrochloride) Cat. No.: HY-135336A

(S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits **leukotriene C4 (LTC4)** and **calcein** transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells.



Purity: 99.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(S)-Verapamil-d6 hydrochloride

((S)-(-)-Verapamil-d6 hydrochloride) Cat. No.: HY-135336AS1

(S)-Verapamil-d6 ((S)-(-)-Verapamil-d6) hydrochloride is the deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits **leukotriene C4 (LTC4)** and **calcein** transport by MRP1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

(±)-Praeruptorin A

Cat. No.: HY-N0081

(±)-Praeruptorin A is the di-esterified product of cis-khellactone (CKL) and the major active ingredient in Peucedani Radix which consists of the dried roots of Peucedanum praeruptorumDunn (Apiaceae).



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

1,2,4-Trihydroxybenzene

Cat. No.: HY-W010451

1,2,4-Trihydroxybenzene (Hydroxyhydroquinone), a by-product of coffee bean roasting, increases intracellular Ca^{2+} concentration in rat thymic lymphocytes.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

1-Octanol

(Octanol) Cat. No.: HY-W032013

1-Octanol (Octanol), a saturated fatty alcohol, is a **T-type calcium channels (T-channels)** inhibitor with an IC_{50} of 4 μM for native T-currents. 1-Octanol is a highly attractive biofuel with diesel-like properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mg

14-Deoxyandrographolide

Cat. No.: HY-N4323

14-Deoxyandrographolide is a labdane diterpene with **calcium channel** blocking activity. 14-Deoxyandrographolide desensitizes hepatocytes to TNF-α-mediated apoptosis through the release of TNFRSF1A release.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

2-Aminoethyl diphenylborinate

(2-APB) Cat. No.: HY-W009724

2-Aminoethyl diphenylborinate (2-APB) is a cell-permeable inhibitor of **IP3R**. 2-Aminoethyl diphenylborinate also inhibits the **store-operated Ca^{2+} (SOC)** channel and activates some **TRP** channels (V1, V2 and V3).



Purity: 98.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

2-Aminoethyl diphenylborinate-d10

(2-APB-d10) Cat. No.: HY-W009724S

2-Aminoethyl diphenylborinate-d10 (2-APB-d10) is the deuterium labeled 2-Aminoethyl diphenylborinate. 2-Aminoethyl diphenylborinate (2-APB) is a cell-permeable inhibitor of **IP3R**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

4-Bromo A23187

Cat. No.: HY-N6694

4-Bromo A23187 is a halogenated analog of the highly selective calcium ionophore A-23187. 4-Bromo A23187a **calcium** modulator, induces **apoptosis** in different cells, including HL-60 cells.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg

8-Bromo-cGMP sodium

Cat. No.: HY-101379A

8-Bromo-cGMP sodium, a membrane-permeable analogue of cGMP, is a **PKG (protein kinase G)** activator. 8-Bromo-cGMP sodium significantly inhibits Ca^{2+} macroscopic currents and impairs insulin release stimulated with high K^+.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ABT-639

Cat. No.: HY-19721

ABT-639 is a novel, peripherally acting, selective T-type Ca^{2+} channel blocker.



Purity: 98.86%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ABT-639 hydrochloride

Cat. No.: HY-101616

ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca^{2+} channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Acetylcholine chloride

(ACh chloride)

Cat. No.: HY-B0282

Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent **cholinergic** agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Acetylcholine-d4 chloride

(ACh-d4 chloride)

Cat. No.: HY-B0282S

Acetylcholine-d9 (ACh-d9) chloride is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent **cholinergic** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Acetylcholine-d9 chloride

(ACh-d9 chloride)

Cat. No.: HY-B0282S1

Acetylcholine-d9 (ACh-d9) chloride is the deuterium labeled Acetylcholine chloride. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent **cholinergic** agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

ACT-709478

Cat. No.: HY-112723

ACT-709478 is a potent, selective, orally active, and brain penetrating **T-type calcium channel** blocker. ACT-709478 is used in the research of generalized epilepsies.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AE0047 Hydrochloride

Cat. No.: HY-U00284

AE0047 Hydrochloride is a **calcium** blocker, used in the research of hypertensive disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amlodipine

Cat. No.: HY-B0317

Amlodipine, an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine can be used for the research of high blood pressure and cancer.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amlodipine besylate

(Amlodipine benzenesulfonate)

Cat. No.: HY-B0317B

Amlodipine besylate (Amlodipine benzenesulfonate), an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amlodipine maleate

Cat. No.: HY-B0317A

Amlodipine maleate is a dihydropyridine **calcium channel** blocker, acts as an orally active **antianginal agent**. Amlodipine maleate blocks the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Amlodipine-1,1,2,2-d4 maleate

Cat. No.: HY-B0317S

Amlodipine-1,1,2,2-d4 maleate is the deuterium labeled Amlodipine.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 25 mg, 50 mg

Amlodipine-d4 besylate

(Amlodipine benzenesulfonate-d4 besylate)

Cat. No.: HY-B0317BS

Amlodipine-d4 (Amlodipine (benzenesulfonate)-d4) besylate is the deuterium labeled Amlodipine besylate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amlodipine-d4 maleate

Cat. No.: HY-B0317AS

Amlodipine-d4 maleate is the deuterium labeled Amlodipine maleate. Amlodipine maleate is a dihydropyridine **calcium channel** blocker, acts as an orally active **antianginal agent**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anipamil

Cat. No.: HY-U00044

Anipamil is a long-acting **calcium channel** blocker, used for the treatment of cardiovascular disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Annonacin

Cat. No.: HY-N2877

Annonacin is an Acetogenin and promotes cytotoxicity via a pathway inhibiting the mitochondrial complex. Annonacin is the active agent found in Graviola leaf extract to act as an inhibitor of **sodium/potassium (NKA)** and **sarcoplasmic reticulum (SERCA) ATPase pumps**.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aranidipine

(MPC1304)

Cat. No.: HY-U00212

Aranidipine (MPC1304) is a **Ca^{2+} channel** antagonist with potent and long-lasting antihypertensive effects.



Purity: 98.67%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Azelnidipine

(CS 905)

Cat. No.: HY-B0023

Azelnidipine(CS 905; Calblock) is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Azelnidipine-d7

(CS-905-d7)

Cat. No.: HY-B0023S

Azelnidipine D7 is deuterium labeled Azelnidipine, which is a L-type calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azumolene

(EU4093 free base)

Cat. No.: HY-113920A

Azumolene (EU4093 free base), a Dantrolene analog, is a muscle relaxant. Azumolene is a **ryanodine receptor (RyR)** modulator and inhibits the calcium-release through ryanodine receptor. Azumolene can be used for malignant hyperthermia research.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Barnidipine

(Mepirodipine; YM-09730-5(Free base)) Cat. No.: HY-107322A

Barnidipine (Mepirodipine) is an L-type calcium antagonist (**CaA**) with high affinity for [^{3}H] initrendipine binding sites (K_i=0.21 nmol/l), has selective action against CaA receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Barnidipine hydrochloride

(Mepirodipine hydrochloride; YM-09730-5) Cat. No.: HY-107322

Barnidipine hydrochloride (Mepirodipine hydrochloride) is an L-type calcium antagonist (**CaA**) with high affinity for [^{3}H] initrendipine binding sites (K_i=0.21 nmol/l), has selective action against CaA receptors.



Purity: 98.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Barnidipine-d4 hydrochloride

Cat. No.: HY-107322AS

Barnidipine-d4 hydrochloride is the deuterium labeled Barnidipine hydrochloride. Barnidipine (Mepirodipine) is an L-type calcium antagonist (**CaA**) with high affinity for [^{3}H] initrendipine binding sites (K_i=0.21 nmol/l), has selective action against CaA receptors.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Barnidipine-d5 hydrochloride (Mepirodipine-d5 hydrochloride; YM-09730-5-d5 hydrochloride)

Cat. No.: HY-107322S

Barnidipine-d5 (Mepirodipine-d5) hydrochloride is the deuterium labeled Barnidipine hydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bay K 8644

Cat. No.: HY-10588

Bay K 8644, a dihydropyridine compound, is a specific **L-type Ca^{2+} channel** agonist. Bay K 8644 increases Ca2+ influx through sarcolemmal Ca^{2+} channels by increasing the open time of the channel.



Purity: 98.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Benidipine

(KW-3049 free base) Cat. No.: HY-B1448A

Benidipine is a potent and orally active calcium channel antagonist. Benidipine shows anti-**apoptosis** effects in ischaemic/reperfused myocardial cells. Benidipine increases the activity of endothelial cell-type nitric oxide synthase and improves coronary circulation in hypertensive rats.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Benidipine hydrochloride

(KW-3049) Cat. No.: HY-B1448

Benidipine hydrochloride is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension).



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Bepridil hydrochloride

(CERM 1978) Cat. No.: HY-103315

Bepridil hydrochloride (CERM 1978) is a **calcium channel** blocker, with antianginal activity.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate)

Cat. No.: HY-16952A

Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting **Ca^+ channel** antagonist and **Na^+**, **K^+** channel inhibitor, with antianginal and type I antiarrhythmic effects.



Purity: 99.73%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Bevantolol hydrochloride

Cat. No.: HY-121186

Bevantolol hydrochloride is a selective **β1** and α1-adrenergic receptor antagonist with **pK_i** values of 7.83, 6.9 in rat cerebral cortex, respectively. Bevantolol hydrochloride is a potent **Ca^{2+}** antagonist.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Bifemelane

(MCI-2016 free base)

Cat. No.: HY-B1558

Bifemelane is a nootropic compound. Bifemelan causes the first peak by stimulating release from intracellular Ca^{2+} stores and the second by capacitive entry through store–operated Ca^{2+} channels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bupivacaine hydrochloride

Cat. No.: HY-B0405A

Bupivacaine hydrochloride is a **NMDA receptor** inhibitor.Bupivacaine can block **sodium**, **L-calcium**, and **potassium channels**.Bupivacaine potently blocks **SCN5A channels** with the IC_{50} of 69.5 μM. Bupivacaine hydrochloride can be used for the research of chronic pain.



Purity: 99.41%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Bupivacaine-d9

Cat. No.: HY-B0405S

Bupivacaine-d9 is a deuterium labeled Bupivacaine. Bupivacaine is a **NMDA receptor** inhibitor.Bupivacaine can block **sodium**, **L-calcium**, and **potassium channels**.Bupivacaine potently blocks **SCN5A channels** with the IC_{50} of 69.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Butamben

(Butyl 4-aminobenzoate)

Cat. No.: HY-B1430

Butamben (Butyl 4-aminobenzoate) results in long-lasting relief from pain, without impairing motor function or other sensory functions.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Butamben-d9

(Butyl 4-aminobenzoate-d9)

Cat. No.: HY-B1430S

Butamben-d9 (Butyl 4-aminobenzoate-d9) is the deuterium labeled Butamben. Butamben (Butyl 4-aminobenzoate) results in long-lasting relief from pain, without impairing motor function or other sensory functions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BX430

Cat. No.: HY-110237

BX430 is a potent and selective noncompetitive allosteric **human P2X4 receptor channels** antagonist with an IC_{50} of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ca2+ channel agonist 1

Cat. No.: HY-41076

Ca^{2+} channel agonist 1 is an agonist of **N-type Ca^{2+} channel** and an inhibitor of **Cdk2**, with EC_{50}s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Calcium channel-modulator-1

Cat. No.: HY-U00135

Calcium channel-modulator-1 is a **calcium channel** modulator; blocks aortic contraction with an IC_{50} of 0.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Calcium ionophore I

(ETH 1001)

Cat. No.: HY-136460

Calcium ionophore I (ETH 1001) is a selective **Ca^{2+} ionophore** for biological membranes.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

CALP1

Cat. No.: HY-P1077

CALP1 is a **calmodulin (CaM)** agonist (K_d of 88 μM) with binding to the **CaM** EF-hand/Ca^{2+}-binding site. CALP1 blocks calcium influx and apoptosis (IC_{50} of 44.78 μM) through inhibition of **calcium channel** opening.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CALP1 TFA

Cat. No.: HY-P1077A

CALP1 TFA is a **calmodulin (CaM)** agonist (K_d of 88 μM) with binding to the **CaM** EF-hand/Ca^{2+}-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC_{50} of 44.78 μM) through inhibition of **calcium channel** opening.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CALP2

Cat. No.: HY-P1076

CALP2 is a **calmodulin (CaM)** antagonist ((K_d of 7.9 μM)) with high affinity for binding to the **CaM** EF-hand/Ca^{2+}-binding site. CALP2 inhibits **CaM**-dependent **phosphodiesterase** activity and increases intracellular Ca^{2+} concentrations.

VKFGVGFKVMVF

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CALP2 TFA

Cat. No.: HY-P1076A

CALP2 TFA is a **calmodulin (CaM)** antagonist (K_d of 7.9 μM) with high affinity for binding to the **CaM** EF-hand/Ca^{2+}-binding site. CALP2 TFA inhibits **CaM**-dependent **phosphodiesterase** activity and increases intracellular Ca^{2+} concentrations.

VKFGVGFKVMVF (TFA salt)

Purity: 98.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CALP3

Cat. No.: HY-P1075

CALP3, a Ca^{2+}-like peptide, is a potent **Ca^{2+} channel** blocker that activates EF hand motifs of Ca^{2+}-binding proteins. CALP3 can functionally mimic increased $[Ca^{2+}]_i$ by modulating the activity of Calmodulin (CaM), Ca^{2+} channels and pumps.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CALP3 TFA

Cat. No.: HY-P1075A

CALP3 TFA, a Ca^{2+}-like peptide, is a potent **Ca^{2+} channel** blocker that activates EF hand motifs of Ca^{2+}-binding proteins. CALP3 TFA can functionally mimic increased $[Ca^{2+}]_i$ by modulating the activity of Calmodulin (CaM), Ca^{2+} channels and pumps.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carboxyamidotriazole

(L-651582; CAI)

Cat. No.: HY-16126

Carboxyamidotriazole (L-651582) is a cytostatic inhibitor of **nonvoltage-operated calcium channels** and **calcium channel-mediated signaling pathways**. Carboxyamidotriazole shows anti-tumor, anti-inflammatory and antiangiogenic effects.



Purity: ≥95.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg

Carboxyamidotriazole Orotate

(L-651582 Orotate; CAI Orotate)

Cat. No.: HY-16125

Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Catharanthine

((+)-3,4-Didehydrocoronaridine)

Cat. No.: HY-N0252

Catharanthine is an alkaloid isolated from Madagascar periwinkle, inhibits **voltage-operated L-type Ca^{2+} channel**, with anti-cancer and blood pressure-lowering activity.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Catharanthine Sulfate

((+)-3,4-Didehydrocoronaridine Sulfate)

Cat. No.: HY-N0252B

Catharanthine Sulfate ((+)-3,4-Didehydrocoronaridine Sulfate) is an alkaloid isolated from Madagascar periwinkle, inhibits **voltage-operated L-type Ca^{2+} channel**, with anti-cancer and blood pressure-lowering activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Catharanthine Tartrate

((+)-3,4-Didehydrocoronaridine Tartrate)

Cat. No.: HY-N0252A

Catharanthine Tartrate is an alkaloid isolated from Madagascar periwinkle, inhibits **voltage-operated L-type Ca^{2+} channel**, with anti-cancer and blood pressure-lowering activity.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Cav 2.2 blocker 1

Cat. No.: HY-119373

Cav 2.2 blocker 1 (compound 9) is a **N-type calcium channel (Cav 2.2)** blocker for the treatment of pain, with an IC_{50} of 1 nM.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cav 2.2 blocker 2

Cat. No.: HY-132268

Cav 2.2 blocker 2 is a **Cav2.2 calcium channel** blocker extracted from patent WO2017046581A1, compound 1. Cav 2.2 blocker 2 can reverses hyperalgesia associated with an injury or inflammation in conjunction with the opioid.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CaV1.3 antagonist-1

Cat. No.: HY-134542

CaV1.3 antagonist-1 is a potent and highly selective **Ca_V1.3 L-type calcium channel (LTCC)** antagonist with an IC_{50} of 1.7 μM. CaV1.3 antagonist-1 inhibits Ca_V1.3 LTCC >600-fold more potently than Ca_V1.2 LTCC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDN1163

Cat. No.: HY-101455

CDN1163 is an allosteric **sarco/endoplasmic reticulum Ca^{2+}-ATPase (SERCA)** activator that improves Ca^{2+} homeostasis. CDN1163 attenuates diabetes and metabolic disorders.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cilnidipine

(FRC-8653)

Cat. No.: HY-17404

Cilnidipine is a long-acting, second-generation dihydropyridine **Ca^{2+}-channel** blocker on L and N-type Ca^{2+} channel. Antihypertensive effects.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Cilnidipine-d7

(FRC-8653-d7)

Cat. No.: HY-17404S

Cilnidipine-d7 is deuterium labeled Cilnidipine. Cilnidipine is a long-acting, second-generation dihydropyridine Ca2+-channel blocker on L and N-type Ca2+ channel. Antihypertensive effects.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Cinepazide

Cat. No.: HY-66010A

Cinepazide is a piperazine derivative and acts as a weak **calcium channel** blocker. Cinepazide is a potent **vasodilator** and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Cinepazide Maleate

(MD-67350)

Cat. No.: HY-66010

Cinepazide Maleate (MD-67350) is a piperazine derivative and acts as a weak **calcium channel** blocker. Cinepazide Maleate is a potent **vasodilator** and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al.</br>.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Cinnarizine

Cat. No.: HY-B1090

Cinnarizine is an antihistamine and a calcium channel blocker, promote cerebral blood flow, used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis.



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Cinnarizine D8

Cat. No.: HY-B1090S

Cinnarizine D8 is a deuterium labeled Cinnarizine. Cinnarizine is an antihistamine and a calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Clevidipine

Cat. No.: HY-17436

Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV) under development for treatment of perioperative hypertension.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Clevidipine-d5

Cat. No.: HY-17436S

Clevidipine-d5 is the deuterium labeled Clevidipine. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC_{50}= 7.1 nM, V(H) = -40 mV) under development for treatment of perioperative hypertension.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Clevidipine-d7

Cat. No.: HY-17436S1

Clevidipine-d7 is the deuterium labeled Clevidipine. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC_{50}= 7.1 nM, V(H) = -40 mV) under development for treatment of perioperative hypertension.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CP-060

Cat. No.: HY-U00354

CP-060 is a potent **Ca^{2+}** antagonist, inhibits Ca^{2+} overload and possesses antioxidant and cardioprotective activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cromolyn sodium

(Disodium Cromoglycate; FPL-670)

Cat. No.: HY-B0320A

Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic drug. Cromolyn sodium is a **GSK-3β** inhibitor with an **IC_{50}** of 2.0 μM.



Purity: 99.10%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Cromolyn-d5 sodium

(Disodium Cromoglycate-d5; FPL-670-d5)

Cat. No.: HY-B0320AS

Cromolyn-d5 sodium (Disodium Cromoglycate-d5) is the deuterium labeled Cromolyn sodium. Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic drug. Cromolyn sodium is a **GSK-3β** inhibitor with an **IC_{50}** of 2.0 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CV-159

Cat. No.: HY-19025

CV-159 is a unique dihydropyridine **Ca^{2+}** antagonist with an anti-calmodulin (CaM) action, and has antiinflammatory activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cycleanine

Cat. No.: HY-N2005

Cycleanine is a potent vascular selective **Calcium** antagonist. Cycleanine has analgesic, muscle relaxant and anti-inflammatory activities. Cycleanine has potential for anti-ovarian cancer acting through the **apoptosis** pathway.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cyclic ADP-ribose

(cADPR)

Cat. No.: HY-N7395

Cyclic ADP-ribose (cADPR) is a potent second messenger for **calcium mobilization** that is synthesized from NAD^+ by an ADP-ribosyl cyclase.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 500 μg

Cyclic ADP-ribose ammonium

(cADPR ammonium)

Cat. No.: HY-N7395A

Cyclic ADP-ribose ammonium (cADPR ammonium) is a potent second messenger for **calcium mobilization** that is synthesized from NAD^+ by an ADP-ribosyl cyclase.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 500 μg

Cyclopiazonic acid

Cat. No.: HY-N6771

Cyclopiazonic acid (CPA), a neurotoxic secondary metabolite (SM) made by A. flavus, is a nanomolar inhibitor of endoplasmic reticulum calcium ATPase (**Ca^{2+}ATPase**; SERCA) and a potent inducer of cell death in plants.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Dantrolene sodium

(F 440)

Cat. No.: HY-14657

Dantrolene sodium is a inhibitor of calcium channel proteins, inhibiting the release of Ca2+ from the sarcoplasm. Dantrolene sodium is a skeletal muscle relaxant which acts by blocking muscle contraction beyond the neuromuscular junction.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dantrolene sodium hemiheptahydrate

(Dantrolene sodium hydrate)

Cat. No.: HY-12542A

Dantrolene sodium hemiheptahydrate is a skeletal muscle relaxant which acts by blocking muscle contraction beyond the neuromuscular junction. Dantrolene sodium hemiheptahydrate is a inhibitor of calcium channel proteins, inhibiting the release of Ca2+ from the sarcoplasm.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Darodipine

(PY 108-068; PY-108068)

Cat. No.: HY-U00086

Darodipine (PY 108-068, PY-108068) is a potent **calcium channel** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dehydronitrosonisoldipine

Cat. No.: HY-Z0816

Dehydronitrosonisoldipine is a **calcium channel** antagonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

DHBP dibromide

(Diheptylviologen dibromide)

Cat. No.: HY-101237

DHBP dibromide is an inhibitor for **calcium** release and a muscle relaxant.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Diltiazem

Cat. No.: HY-B0632

Diltiazem is an orally active **L-type Ca^{2+} channel** blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Diltiazem hydrochloride

(CRD-401)

Cat. No.: HY-14656

Diltiazem hydrochloride is a **Ca^{2+}** influx inhibitor (slow channel blocker or calcium antagonist).



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Diltiazem-(acetoxy-d3) (hydrochloride)

Cat. No.: HY-14656S1

Diltiazem-(acetoxy-d3) hydrochloride is the deuterium labeled Diltiazem hydrochloride. Diltiazem hydrochloride is a **Ca^{2+}** influx inhibitor (slow channel blocker or calcium antagonist).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Diltiazem-d3 hydrochloride

Cat. No.: HY-14656S

Diltiazem-d3 hydrochloride is the deuterium labeled Diltiazem hydrochloride. Diltiazem hydrochloride is a **Ca^{2+}** influx inhibitor (slow channel blocker or calcium antagonist).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Diltiazem-d4 hydrochloride

Cat. No.: HY-B0632S1

Diltiazem-d4 hydrochloride is the deuterium labeled Diltiazem. Diltiazem is an orally active **L-type Ca^{2+} channel** blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Diltiazem-d6

Cat. No.: HY-B0632S

Diltiazem-d6 is the deuterium labeled Diltiazem. Diltiazem is an orally active **L-type Ca^{2+} channel** blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

DL-Phenylalanine-d5 hydrochloride

(2-Amino-3-phenylpropionic acid-d5 hydrochloride)

Cat. No.: HY-N0215S6

DL-Phenylalanine-d5 (2-Amino-3-phenylpropionic acid-d5) hydrochloride is the deuterium labeled DL-Phenylalanine hydrochloride. L-Phenylalanine hydrochloride is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dopropidil

Cat. No.: HY-U00151

Dopropidil is a novel anti-anginal calcium ion modulating agent, possessing intracellular calcium antagonist activity and anti-ischemic effects in several predictive animal models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dronedarone

(SR 33589)

Cat. No.: HY-A0016

Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class Ⅲ **antiarrhythmic agent** for the study of atrial fibrillation (AF) and atrial flutter.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Dronedarone D6 hydrochloride

Cat. No.: HY-A0016S

Dronedarone D6 hydrochloride is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class Ⅲ **antiarrhythmic agent** for the study of atrial fibrillation (AF) and atrial flutter.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Drotaverine hydrochloride

Cat. No.: HY-108974

Drotaverine (hydrochloride) is a type **4 cyclic nucleotide phosphodiesterase (PDE4)** inhibitor and an **L-type voltage-dependent calcium channel (L-VDCC)** blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Drotaverine-d10 hydrochloride

Cat. No.: HY-108974S

Drotaverine-d10 hydrochloride is the deuterium labeled Drotaverine hydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DS16570511

Cat. No.: HY-115595

DS16570511 is cell-permeable inhibitor of the **mitochondrial calcium uniporter**, which blocks the MCU- or MICU1-dependent increase of Ca^{2+} influx.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ebselen

(SPI-1005; PZ-51; CCG-39161)

Cat. No.: HY-13750

Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent **voltage-dependent calcium channel (VDCC)** blocker. Ebselen potently inhibits M^{pro} (IC_{50}=0.67 μM) and **COVID-19** virus (EC_{50}=4.67 μM).Ebselen is an inhibitor of **HIV-1** capsid CTD dimerization.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Efonidipine

(NZ-105; (±)-Efonidipine) Cat. No.: HY-12502

Efonidipine(NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Efonidipine hydrochloride

(NZ-105 hydrochloride) Cat. No.: HY-12502B

Efonidipine Hcl (NZ-105) is a dual T-type and L-type calcium channel blocker (CCB).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Efonidipine hydrochloride monoethanolate

(NZ-105 hydrochloride monoethanolate) Cat. No.: HY-12502A

Efonidipine hydrochloride monoethanolate (NZ-105 hydrochloride monoethanolate) is a dual T-type and L-type calcium channel blocker (CCB).



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ethacrynic acid

(Etacrynic acid) Cat. No.: HY-B1640

Ethacrynic acid (Etacrynic acid) is a diuretic. Ethacrynic acid is an inhibitor of **glutathione S-transferases (GSTs)**. Ethacrynic acid is a potent inhibitor of **NF-kB-signaling** pathway, and also modulates leukotriene formation.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Ethacrynic acid D5

Cat. No.: HY-108538

Ethacrynic acid D5 is a deuterium labeled Ethacrynic acid. Ethacrynic acid is a diuretic. Ethacrynic acid is an inhibitor of **glutathione S-transferases (GSTs)**. Ethacrynic acid is a potent inhibitor of **NF-kB-signaling** pathway, and also modulates leukotriene formation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ethosuximide

Cat. No.: HY-B1378

Ethosuximide, a widely prescribed anti-epileptic drug, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type **calcium channel**.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Ethosuximide-d3

Cat. No.: HY-B1378S

Ethosuximide-d3 is the deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic drug, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type **calcium channel**.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg, 25 mg

Ethosuximide-d5

Cat. No.: HY-B1378S1

Ethosuximide-d5 is deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic drug, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Etiracetam

(UCB 6474) Cat. No.: HY-B0106A

Etiracetam (UCB 6474) is an **acetylcholine** agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Etiracetam-d3

(UCB 6474-d3) Cat. No.: HY-B0106AS

Etiracetam-d3 (UCB 6474-d3) is the deuterium labeled Etiracetam. Etiracetam (UCB 6474) is an **acetylcholine** agonist and a nootropic drug of the racetam family. Less active than its S-enantiomer Levetiracetam (UCB L059).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Etripamil

(MSP-2017; (-)-MSP-2017) Cat. No.: HY-17611

Etripamil (MSP-2017) is a short-acting **L-type calcium-channel** antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT).



Purity: 98.68%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Fantofarone

(SR 33557) Cat. No.: HY-105117

Fantofarone is a highly potent **Calcium Channel** antagonist.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fasudil

(HA-1077; AT877) Cat. No.: HY-10341A

Fasudil (HA-1077; AT877), is a nonspecific **RhoA/ROCK** inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC_{50}s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fasudil Hydrochloride

(HA-1077 Hydrochloride; AT-877 Hydrochloride) Cat. No.: HY-10341

Fasudil Hydrochloride (HA-1077 Hydrochloride; AT877 Hydrochloride), is a nonspecific **RhoA/ROCK** inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC_{50}s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Felodipine

Cat. No.: HY-B0309

Felodipine, a dihydropyridine, is a potent, vasoselective **calcium channel** antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels.



Purity: 98.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Felodipine-d3

Cat. No.: HY-B0309S2

Felodipine-d3 is the deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective **calcium channel** antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Felodipine-d5

Cat. No.: HY-B0309S1

Felodipine-d5 is deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Felodipine-d8

Cat. No.: HY-B0309S

Felodipine-d8 is the deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective **calcium channel** antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

Fendiline hydrochloride

Cat. No.: HY-B0984

Fendiline hydrochloride is a nonselective calcium channel blocker.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Fenoverine

(Spasmopriv) Cat. No.: HY-107349

Fenoverine is an **antispasmodic** drug and inhibits **calcium channel** currents. Fenoverine induces rhabdomyolysis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flufenamic acid

Cat. No.: HY-B1221

Flufenamic acid is a non-steroidal anti-inflammatory agent, inhibits cyclooxygenase (**COX**), activates **AMPK**, and also modulates ion channels, blocking **chloride channels** and **L-type Ca^{2+} channels**, modulating non-selective cation channels (**NSC**), activating...



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Flufenamic acid-d4

Cat. No.: HY-B1221S

Flufenamic acid-d4 is deuterium labeled Flufenamic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flunarizine dihydrochloride

Cat. No.: HY-B0358A

Flunarizine dihydrochloride is a potent dual **Na^+/Ca^{2+} channel (T-type)** blocker. Flunarizine dihydrochloride is a **D_2 dopamine** receptor antagonist.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Fluspirilene

(R 6218; Redeptin)

Cat. No.: HY-B1655

Fluspirilene is a non-competitive antagonist of **L-type calcium channels** with an **IC_{50}** of 0.03 μM. Fluspirileneis a long-acting injectable depot antipsychotic drug used for schizophrenia.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

FPL64176

Cat. No.: HY-103307

FPL64176, a nondihydropyridine compound, is a potent agonist of **L-type Ca^{2+} channels** with an **EC_{50}** value of 16 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gabapentin

Cat. No.: HY-A0057

Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Gabapentin enacarbil

(XP-13512)

Cat. No.: HY-16216

Gabapentin enacarbil (XP-13512) is a prodrug for the anticonvulsant and analgesic drug gabapentin.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gabapentin enacarbil-d6

(XP-13512-d6)

Cat. No.: HY-16216S

Gabapentin enacarbil-d6 (XP-13512-d6) is the deuterium labeled Gabapentin enacarbil. Gabapentin enacarbil (XP-13512) is a prodrug for the anticonvulsant and analgesic drug gabapentin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gabapentin hydrochloride

Cat. No.: HY-A0057A

Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Gabapentin-13C3

Cat. No.: HY-A0057S2

Gabapentin-13C3 is the 13C-labeled Gabapentin. Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gabapentin-d4

Cat. No.: HY-A0057S

Gabapentin-d4 is the deuterium labeled Gabapentin. Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Gabapentin-d6

Cat. No.: HY-A0057S1

Gabapentin-d6 is the deuterium labeled Gabapentin. Gabapentin (Neurontin) is a pharmaceutical drug, specifically a GABA analog. It was originally developed to treat epilepsy, and currently is also used to relieve neuropathic pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

Gabapentin-d6 hydrochloride

Cat. No.: HY-A0057AS

Gabapentin-d6 (hydrochloride) is deuterium labeled Gabapentin (hydrochloride).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gallopamil

(Methoxyverapamil)

Cat. No.: HY-14276

Gallopamil (Methoxyverapamil), a methoxy derivative of Verapamil, is a **phenylalkylamine calcium** antagonist. Gallopamil inhibits acid secretion in a concentration-dependent manner with an IC_{50} of 10.9 μM. Gallopamil is a potent antiarrhythmic and vasodilator agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gallopamil hydrochloride

(Methoxyverapamil hydrochloride)

Cat. No.: HY-14276A

Gallopamil hydrochloride (Methoxyverapamil hydrochloride), a methoxy derivative of Verapamil, is a **phenylalkylamine calcium** antagonist. Gallopamil hydrochloride inhibits acid secretion in a concentration-dependent manner with an IC_{50} of 10.9 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rd

(Gypenoside VIII)

Cat. No.: HY-N0043

Ginsenoside Rd inhibits TNFα-induced **NF-κB** transcriptional activity with an IC_{50} of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of **COX-2** and **iNOS** mRNA. Ginsenoside Rd also inhibits Ca^{2+} influx.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Rf

(Panaxoside Rf)

Cat. No.: HY-N0601

Ginsenoside Rf is a trace component of ginseng root. Ginsenoside Rf inhibits **N-type Ca^{2+} channel**.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V)

Cat. No.: HY-N0607

Ginsenoside Ro (Polysciasaponin P3; Chikusetsusaponin 5; Chikusetsusaponin V) exhibits a Ca^{2+}-antagonistic antiplatelet effect with an IC_{50} of 155 μM. Ginsenoside Ro reduces the production of TXA_2 more than it reduces the activities of COX-1 and TXAS.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glaucine

(O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396)

Cat. No.: HY-N3945

Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum Crantz with antitussive, bronchodilation and anti-inflammatory properties.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Glaucine-d6 (O,O-Dimethylisoboldine-d6; S-(+)-Glaucine-d6; NSC 34396-d6)

Cat. No.: HY-N3945S

Glaucine-d6 (O,O-Dimethylisoboldine-d6) is the deuterium labeled Glaucine. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum Crantz with antitussive, bronchodilation and anti-inflammatory properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gomisin J

Cat. No.: HY-N0385

Gomisin J is a small molecular weight lignan found in Schisandra chinensis and has been demonstrated to have vasodilatory activity.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

GSK-7975A

Cat. No.: HY-12507

GSK-7975A is a potent and orally available **CRAC** channel inhibitor.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK1016790A

Cat. No.: HY-19608

GSK1016790A is a potent and selective **transient receptor potential vanilloid 4 (TRPV4)** channel agonist. GSK1016790A can elicit Ca^{2+} influx and elevate intracellular Ca^{2+} in HEK cells.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GV-58

Cat. No.: HY-12498

GV-58 is a potent, selective N- and P/Q-type Ca2+ channels agonist with EC50 of 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel; 20-fold less potent CDK inhibitor activity.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Halofuginone

(RU-19110)

Cat. No.: HY-N1584

Halofuginone (RU-19110), a Febrifugine derivative, is a competitive **prolyl-tRNA synthetase** inhibitor with a K_i of 18.3 nM. Halofuginone is a specific inhibitor of **type-I collagen** synthesis and attenuates osteoarthritis (OA) by inhibition of **TGF-β** activity.



Purity: 98.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Halofuginone hydrobromide

(RU-19110 hydrobromide)

Cat. No.: HY-N1584A

Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive **prolyl-tRNA synthetase** inhibitor with a K_i of 18.3 nM.



Purity: 99.55%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Heteroclitin D

Cat. No.: HY-N2077

Heteroclitin D is a lignin from Kadsura medicinal plants with anti-liqid peroxidation. Heteroclitin D inhibits L-type **calcium channels**.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HSK16149

Cat. No.: HY-142240

HSK16149 is a novel ligand of **voltage-gated calcium channel (VGCC) α 2 δ subunit**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Huwentoxin XVI

Cat. No.: HY-P1078

Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel** (IC_{50} of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Huwentoxin XVI TFA

Cat. No.: HY-P1078A

Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel** (IC_{50} of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hyperforin dicyclohexylammonium salt

(Hyperforin DCHA) Cat. No.: HY-116330A

Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a **transient receptor canonical 6 (TRPC6)** channels activator. Hyperforin dicyclohexylammonium salt modulates Ca^{2+} levels by activating Ca^{2+}-conducting non-selective canonical TRPC6 channels.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Ibutilide fumarate

(U70226E) Cat. No.: HY-B0387

Ibutilide fumarate is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ibutilide-d5 fumarate

(U70226E-d5) Cat. No.: HY-B0387S

Ibutilide-d5 (hemifumarate) is deuterium labeled Ibutilide (fumarate).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Iganidipine

Cat. No.: HY-101685

Iganidipine is a **Ca^{2+}** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ILS-920

Cat. No.: HY-106345

ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin **FKBP52** and to the β1-subunit of **L-type voltage-gated calcium channels (VGCC)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ionomycin

(SQ23377) Cat. No.: HY-13434

Ionomycin (SQ23377) is a potent, selective **calcium ionophore** and an antibiotic produced by Streptomyces conglobatus. Ionomycin (SQ23377) is highly specific for divalent cations (Ca>Mg>Sr=Ba). Ionomycin (SQ23377) promotes **apoptosis**.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mg (14.1 mM * 1 mL in Ethanol)

Ionomycin calcium

(SQ23377 calcium) Cat. No.: HY-13434A

Ionomycin calcium (SQ23377 calcium) is a potent, selective **calcium ionophore** and an antibiotic produced by Streptomyces conglobatus. Ionomycin calcium (SQ23377 calcium) is highly specific for divalent cations (Ca>Mg>Sr=Ba). Ionomycin (SQ23377) promotes **apoptosis**.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Isotachysterol 3

Cat. No.: HY-130704

Isotachysterol 3 is an analog of 1,25-dihydrox Vitamin D3. Isotachysterol 3 stimulates intestinal **calcium transport** and bone calcium mobilization in anephric rats.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Isradipine

(PN 200-110) Cat. No.: HY-B0233

Isradipine (PN 200-110) is an orally active **L-type calcium channel** blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation.



Purity: 99.69%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Isradipine-d3

Cat. No.: HY-B0233S

Isradipine-d3 (PN 200-110-d3) is the deuterium labeled Isradipine. Isradipine (PN 200-110) is an orally active **L-type calcium channel** blocker.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Istaroxime hydrochloride

(PST2744 hydrochloride) Cat. No.: HY-15718A

Istaroxime hydrochloride is a **Na^+/K^+-ATPase** inhibitor (**IC_{50}**=0.11 μM) and a sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (**SERCA 2**) activator.



Purity: 99.32%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ISX-9

(Isoxazole 9) Cat. No.: HY-12323

ISX-9 (Isoxazole 9) is a potent inducer of adult neural stem cell differentiation. ISX-9 activates Ca^{2+} influx through both voltage-gated Ca^{2+} channels and NMDA receptors and increases neuroD expression.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ITH12575

Cat. No.: HY-117073

ITH12575, a CGP37157 derivative, is a potent and selective **mNCX** blocker. ITH12575 reduces Ca^{2+} influx through CALHM1 at low micromolar concentrations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-26489112

Cat. No.: HY-12596

JNJ-26489112, a CNS-active agent, exhibits broad-spectrum anticonvulsant activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JTV-519 free base

(K201 free base) Cat. No.: HY-15293A

JTV-519 free base (K201 free base) is a Ca^{2+}-dependent blocker of sarcoplasmic reticulum Ca^{2+}-stimulated ATPase (**SERCA**) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JTV-519 hemifumarate

(K201 hemifumarate) Cat. No.: HY-15293B

JTV-519 hemifumarate (K201 hemifumarate) is a Ca^{2+}-dependent blocker of sarcoplasmic reticulum Ca^{2+}-stimulated ATPase (**SERCA**) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 1 mg

L-Ascorbic acid

(L-Ascorbate; Vitamin C) Cat. No.: HY-B0166

L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively **$Ca_v3.2$ channels** with an **IC_{50}** of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

L-Ascorbic acid sodium salt

(Sodium L-ascorbate; Vitamin C sodium salt) Cat. No.: HY-B0166A

L-Ascorbic acid sodium salt (Sodium L-ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt inhibits selectively **$Ca_v3.2$ channels** with an **IC_{50}** of 6.5 μM.



Purity: 99.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

L-Ascorbic acid-13C

(L-Ascorbate-13C; Vitamin C-13C) Cat. No.: HY-B0166S1

L-Ascorbic acid-13C (L-Ascorbate-13C) is the 13C-labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively **$Ca_v3.2$ channels** with an **IC_{50}** of 6.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Ascorbic acid-13C6

(L-Ascorbate-13C6; Vitamin C-13C6) Cat. No.: HY-B0166S

L-Ascorbic acid-13C6 (L-Ascorbate-13C6) is the 13C-labeled L-Ascorbic acid. L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively **$Ca_v3.2$ channels** with an **IC_{50}** of 6.5 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine

((S)-2-Amino-3-phenylpropionic acid) Cat. No.: HY-N0215

L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a **α2δ subunit of voltage-dependent Ca^{+} channels** antagonist with a K_i of 980 nM.



Purity: 99.30%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 1 g

L-Phenylalanine-13C

((S)-2-Amino-3-phenylpropionic acid-13C) Cat. No.: HY-N0215S2

L-Phenylalanine-13C ((S)-2-Amino-3-phenylpropionic acid-13C) is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-13C6

((S)-2-Amino-3-phenylpropionic acid-13C6) Cat. No.: HY-N0215S8

L-Phenylalanine-13C6 ((S)-2-Amino-3-phenylpropionic acid-13C6) is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-13C9

((S)-2-Amino-3-phenylpropionic acid-13C9) Cat. No.: HY-N0215S10

L-Phenylalanine-13C9 ((S)-2-Amino-3-phenylpropionic acid-13C9) is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-13C9,15N

((S)-2-Amino-3-phenylpropionic acid-13C9,15N) Cat. No.: HY-N0215S11

L-Phenylalanine-13C9,15N ((S)-2-Amino-3-phenylpropionic acid-13C9,15N) is the 13C- and 15N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-13C9,d8,15N

((S)-2-Amino-3-phenylpropionic acid-13C9,d8,15N) Cat. No.: HY-N0215S9

L-Phenylalanine-13C9,d8,15N ((S)-2-Amino-3-phenylpropionic acid-13C9,d8,15N) is the deuterium, 13C-, and 15-labeled L-Phenylalanine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-15N

((S)-2-Amino-3-phenylpropionic acid-15N) Cat. No.: HY-N0215S5

L-Phenylalanine-15N ((S)-2-Amino-3-phenylpropionic acid-15N) is the 15N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

L-Phenylalanine-15N,d8

((S)-2-Amino-3-phenylpropionic acid-15N,d8) Cat. No.: HY-N0215S14

L-Phenylalanine-15N,d8 ((S)-2-Amino-3-phenylpropionic acid-15N,d8) is the deuterium and 15N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-3-13C

((S)-2-Amino-3-phenylpropionic acid-3-13C) Cat. No.: HY-N0215S7

L-Phenylalanine-3-13C ((S)-2-Amino-3-phenylpropionic acid-3-13C) is the 13C-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-d1

((S)-2-Amino-3-phenylpropionic acid-d1) Cat. No.: HY-N0215S13

L-Phenylalanine-d1 ((S)-2-Amino-3-phenylpropionic acid-d1) is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-d2

((S)-2-Amino-3-phenylpropionic acid-d2)

Cat. No.: HY-N0215S3

L-Phenylalanine-d2 ((S)-2-Amino-3-phenylpropionic acid-d2) is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Phenylalanine-d5

Cat. No.: HY-N0215S12

L-Phenylalanine-d5 is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

L-Phenylalanine-d7

((S)-2-Amino-3-phenylpropionic acid-d7)

Cat. No.: HY-N0215S

L-Phenylalanine-d7 ((S)-2-Amino-3-phenylpropionic acid-d7) is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 25 mg, 100 mg

L-Phenylalanine-d8

((S)-2-Amino-3-phenylpropionic acid-d8)

Cat. No.: HY-N0215S1

L-Phenylalanine-d8 ((S)-2-Amino-3-phenylpropionic acid-d8) is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Lacidipine

Cat. No.: HY-B0347

Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker. Target: Calcium Channel Lacidipine, a novel third-generation dihydropyridine calcium channel blocker, has been demonstrated effective for hypertension.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Lacidipine-d10

Cat. No.: HY-B0347S

Lacidipine-d10 is the deuterium labeled Lacidipine. Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Lemildipine

(NB-818; NPK-1886)

Cat. No.: HY-19663

Lemildipine is a new dihydropyridine **calcium** entry blocker.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lercanidipine

Cat. No.: HY-B0612

Lercanidipine is a lipophilic third-generation dihydropyridine-**calcium channel** blocker (DHP-CCB). Lercanidipine has long lasting antihypertensive action and reno-protective effect.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Lercanidipine hydrochloride

Cat. No.: HY-B0612A

Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-**calcium channel** blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Lercanidipine-13C,d3-1 hydrochloride

Cat. No.: HY-B0612AS1

Lercanidipine-13C,d3-1 (hydrochloride) is deuterium labeled Lercanidipine (hydrochloride). Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lercanidipine-d3 hydrochloride

Cat. No.: HY-B0612DS1

Lercanidipine-d3 hydrochloride is the deuterium labeled Lercanidipine. Lercanidipine is a lipophilic third-generation dihydropyridine-**calcium channel** blocker (DHP-CCB).



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Levamlodipine

((S)-Amlodipine; Levoamlodipine) Cat. No.: HY-14744

Levamlodipine ((S)-Amlodipine) is a powerful dihydropyridine **calcium channel** blocker, possessing vasodilation properties and used in the treatment of hypertension and angina.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Levamlodipine besylate

((S)-Amlodipine besylate; Levoamlodipine besylate) Cat. No.: HY-14744A

Levamlodipine besylate ((S)-Amlodipine besylate) is a powerful dihydropyridine **calcium channel** blocker, possessing vasodilation properties and used in the treatment of hypertension and angina.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Levamlodipine-d4

((S)-Amlodipine-d4; Levoamlodipine-d4) Cat. No.: HY-14744S

Levamlodipine-d4 ((S)-Amlodipine-d4) is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine) is a powerful dihydropyridine **calcium channel** blocker, possessing vasodilation properties and used in the treatment of hypertension and angina.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Lidoflazine

Cat. No.: HY-112075

Lidoflazine is a high affinity blocker of the **HERG (human ether-a-go-go-related gene) K^+** channel. Lidoflazine is an antianginal **calcium channel** blocker that carries a significant risk of QT interval prolongation and ventricular arrhythmia.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Lomerizine dihydrochloride

(KB-2796) Cat. No.: HY-B0768A

Lomerizine dihydrochloride is an antagonist of **L-** and **T-type voltagegated calcium channels**.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Manidipine

Cat. No.: HY-B0419

Manidipine is a calcium channel blocker that is used clinically as an antihypertensive.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Manidipine dihydrochloride

(CV-4093) Cat. No.: HY-17403

Manidipine dihydrochloride (CV-4093) is a dihydropyridine compound and a calcium channel blocker for Ca2+ current with IC50 of 2.6 nM.



Purity: 98.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Manidipine-d4

Cat. No.: HY-B0419S

Manidipine-d4 is the deuterium labeled Manidipine. Manidipine is a calcium channel blocker that is used clinically as an antihypertensive.



Purity: >98%
Clinical Data:
Size: 1 mg

McN5691

(RWJ26240) Cat. No.: HY-U00218

McN5691 is a voltage-sensitive **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Menthol-d4

Cat. No.: HY-N1369S

Menthol-d4 is the deuterium labeled Menthol. Menthol is a natural analgesic compound. Menthol could cause a feeling of coolness due to stimulation of 'cold' receptors by inhibiting Ca^{++} currents of neuronal membranes.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg, 100 mg

Methyl homoveratrate

Cat. No.: HY-W042039

Methyl homoveratrate, a metabolite of RWJ-26240 in vivo, can be identified in plasma, urine and faecal extract. McN5691 (RWJ-26240) is a voltage-sensitive calcium channel blocker.



Purity: 97.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Mibefradil

(Ro 40-5967)

Cat. No.: HY-15553

Mibefradil (Ro 40-5967) is a **calcium channel** blocker with moderate selectivity for T-type Ca^{2+} channels displaying **IC_{50}**s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Mibefradil dihydrochloride

(Ro 40-5967 dihydrochloride)

Cat. No.: HY-15553A

Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a **calcium channel** blocker with moderate selectivity for T-type Ca^{2+} channels (**IC_{50}**s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively).



Purity: 98.78%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mirogabalin

(DS5565)

Cat. No.: HY-12650

Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the **α2δ-1** subunit of voltage-sensitive **calcium channel** complexes in the CNS.



Purity: 99.31%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mirogabalin besylate

(DS 5565 besylate)

Cat. No.: HY-108006

Mirogabalin besylate is a selective and orally available ligand for the **α2δ** subunit of **voltage-gated calcium channels**, with **K_d**s of 13.5 nM, 22.7 nM, 27 nM, and 47.6 nM for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2, respectively.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML218

Cat. No.: HY-103309

ML218 is a potent, selective and orally active **T-type Ca^{2+} channels (Cav3.1, Cav3.2, Cav3.3)** inhibitor with **IC_{50}**s of 310 nM and 270 nM for **Cav3.2** and **Cav3.3**, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

ML218 hydrochloride

Cat. No.: HY-103309A

ML218 hydrochloride is a potent, selective and orally active **T-type Ca^{2+} channels (Cav3.1, Cav3.2, Cav3.3)** inhibitor with **IC_{50}**s of 310 nM and 270 nM for **Cav3.2** and **Cav3.3**, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ML218-d9

Cat. No.: HY-103309S

ML218-d9 is the deuterium labeled ML218. ML218 is a potent, selective and orally active **T-type Ca^{2+} channels (Cav3.1, Cav3.2, Cav3.3)** inhibitor with **IC_{50}**s of 310 nM and 270 nM for **Cav3.2** and **Cav3.3**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRS 1523

Cat. No.: HY-121119

MRS 1523 is a potent and selective **adenosine A_3 receptor** antagonist with **K_i** values of 18.9 nM and 113 nM for **human** and **rat A_3 receptors**, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A_1 and A_{2A} receptors, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

MRS1845

Cat. No.: HY-103310

MRS1845 is a selective store-operated calcium (**SOC**) channel inhibitor with an IC_{50} of 1.7 μM. MRS1845 is an **ORAI1** inhibitor.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Myomodulin

Cat. No.: HY-P0268

Myomodulin is a neuropeptide present in molluscs, insects, and gastropods.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

N-type calcium channel blocker-1

Cat. No.: HY-100310

N-type calcium channel blocker-1 is an orally active compound which shows high affinity to functionally block **N-type calcium channels** with an IC_{50} of 0.7 μM in the IMR32 assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N106

Cat. No.: HY-110273

N106 is a first-in-class **sarcoplasmic reticulum calcium ATPase (SERCA2a) SUMOylation** activator. N106 directly activates the SUMO-activating enzyme, E1 ligase. N106 can be used for heart failure research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NecroX-5

Cat. No.: HY-104015

NecroX-5 is a derivative of the NecroX, reduces intracellular **calcium** concentration, and possesses anti-inflammatory and anti-cancer activity.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Ned 19

Cat. No.: HY-103316A

Ned 19 is a selective membrane-permeant non competitive **NAADP** antagonist and inhibits NAADP-mediated Ca^{2+} signaling, with an IC_{50} of 65 nM. Ned 19 strongly inhibits tumor growth and vascularization as well as lung metastases in mice.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ned-K

Cat. No.: HY-131041

Ned-K is a nicotinic acid adenine dinucleotide phosphate (**NAADP**) antagonist. Ned-K is effective at dampening simulated ischaemia and reperfusion (sIR)-induced Ca^{2+} oscillations in cardiomyocytes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nemadipine-A

Cat. No.: HY-126583

Nemadipine-A is a specific inhibitor of the EGL-19 L-type **Ca^{2+} channel**. Nemadipine-A, a cell-permeable L-type calcium channel inhibitor, sensitizes TRAIL-resistant cancer cells to this ligand.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nexopamil racemate

Cat. No.: HY-101727

Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined **Ca^{2+}/5-HT_2** antagonist on thrombus formation in vivo and on platelet aggregation in vitro.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nicardipine

(YC-93 free base)

Cat. No.: HY-12515

Nicardipine (YC-93 free base) is a **calcium channel** blocker with an IC_{50} of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Nicardipine hydrochloride

(YC-93) Cat. No.: HY-12515A

Nicardipine hydrochloride (YC-93) is a **calcium channel** blocker with an IC_{50} of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Nicardipine-d3 hydrochloride

(YC-93-d3) Cat. No.: HY-12515AS

Nicardipine D3 hydrochloride (YC-93 D3) is the deuterium labeled Nicardipine hydrochloride. Nicardipine hydrochloride is a calcium channel blocker with an IC_{50} of 1 μM for blocking cardiac calcium channels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nifedipine

(BAY-a-1040) Cat. No.: HY-B0284

Nifedipine (BAY-a-1040) is a potent **calcium channel** blocker and drug of choice for cardiac insufficiencies.



Purity: 99.35%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g, 10 g

Nifedipine-d4

(BAY-a-1040-d4) Cat. No.: HY-B0284S1

Nifedipine-d4 (BAY-a-1040-d4) is the deuterium labeled Nifedipine. Nifedipine (BAY-a-1040) is a potent **calcium channel** blocker and drug of choice for cardiac insufficiencies.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nifedipine-d6

(BAY-a-1040-d6) Cat. No.: HY-B0284S

Nifedipine D6 (BAY-a-1040 D6) is deuterium labeled nifedipine, and nifedipine is a potent calcium channel blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nilvadipine

(FK235; FR34235) Cat. No.: HY-14284

Nilvadipine is a potent **calcium channel** antagonist, and the IC_{50} value is around 0.1 nM.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Nilvadipine-d4

Cat. No.: HY-14284S

Nilvadipine-d4 is deuterium labeled Nilvadipine. Nilvadipine is a potent calcium channel antagonist, and the IC50 value is around 0.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nimodipine

(BAY-e 9736) Cat. No.: HY-B0265

Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive **dihydropyridine calcium** antagonist. Nimodipine can be used for the research of cerebrovascular disorders.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Nimodipine-d7

Cat. No.: HY-B0265S

Nimodipine-d7 is the deuterium labeled Nimodipine. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive **dihydropyridine calcium** antagonist. Nimodipine can be used for the research of cerebrovascular disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 2 mg, 5 mg, 10 mg

Nisoldipine

(BAY-k 5552) Cat. No.: HY-17402

Nisoldipine(BAY-k 5552; Sular) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM. IC50 value: 10 nM Target: L-type Cav1.2 Nisoldipine is a potent blocker of L-type calcium channels.



Purity: 99.20%
Clinical Data: Launched
Size: 100 mg, 500 mg, 1 g

Nisoldipine-d4

Cat. No.: HY-17402S1

Nisoldipine-d4 (BAY-k 5552-d4) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC_{50} of 10 nM.



Purity: >98%
Clinical Data:
Size: 1 mg

Nisoldipine-d6

(BAY-k 5552-d6)

Cat. No.: HY-17402S

Nisoldipine-d6 (BAY-k 5552-d6) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552; Sular) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with an IC_{50} of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nisoldipine-d7

Cat. No.: HY-17402S2

Nisoldipine-d7 (BAY-k 5552-d7) is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC_{50} of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nitrendipine

(BAY-E-5009)

Cat. No.: HY-B0424

Nitrendipine (BAY-E-5009), an analogue of Nifedipine (HY-B0284), is a dihydropyridine **calcium channel** blocker with vasodilator action. Nitrendipine has antihypertensive effect.



Purity: 99.25%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nitrendipine-d5

(AY-E-5009-d5)

Cat. No.: HY-B0424S

Nitrendipine-d5 (AY-E-5009-d5) is the deuterium labeled Nitrendipine. Nitrendipine (BAY-E-5009), an analogue of Nifedipine (HY-B0284), is a dihydropyridine **calcium channel** blocker with vasodilator action. Nitrendipine has antihypertensive effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NNC 55-0396

(NNC 55-0396 dihydrochloride)

Cat. No.: HY-50722

NNC 55-0396, Mibefradil derivative, is a highly selective T-type calcium channel blocker; displays IC50 values of 6.8 and > 100 μM for inhibition of Cav3.1 T-type channels and HVA currents respectively in INS-1 cells.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Norverapamil

((±)-Norverapamil; D591)

Cat. No.: HY-135328

Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a **L-type calcium channel** blocker and a **P-glycoprotein (P-gp)** function inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Norverapamil hydrochloride

((±)-Norverapamil hydrochloride; D591 hydrochloride)

Cat. No.: HY-100750

Norverapamil hydrochloride ((±)-Norverapamil hydrochloride), an N-demethylated metabolite of Verapamil, is a **L-type calcium channel** blocker and a **P-glycoprotein (P-gp)** function inhibitor.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Norverapamil-d7

((±)-Norverapamil-d7; D591-d7)

Cat. No.: HY-135328S

Norverapamil-d7 ((±)-Norverapamil-d7) is a deuterium labeled Norverapamil ((±)-Norverapamil). Norverapamil, an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Norverapamil-d7 hydrochloride

((±)-Norverapamil-d7 hydrochloride; D591-d7 hydrochloride)

Cat. No.: HY-135328AS

Norverapamil-d7 ((±)-Norverapamil-d7) hydrochloride is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nothofagin

Cat. No.: HY-113919

Nothofagin, a dihydrochalcone, is isolated from rooibos (Aspalathus linearis). Nothofagin downregulates NF-κB translocation through blocking **calcium** influx.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

NP118809

(39-1B4)

Cat. No.: HY-14462

NP118809 is a potent **N-type calcium channel** blocker, with an IC_{50} of 0.11 μM; also less potently inhibits **L-type calcium channel** with an IC_{50} of 12.2 μM.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

NP118809-d8

Cat. No.: HY-14462S

NP118809-d8 is the deuterium labeled NP118809. NP118809 is a potent **N-type calcium channel** blocker, with an IC_{50} of 0.11 μM; also less potently inhibits **L-type calcium channel** with an IC_{50} of 12.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

NS-638

Cat. No.: HY-101428

NS-638 is a small nonpeptide molecule with **Ca^{2+}**-channel blocking properties. K^+-stimulated intracellular Ca^{2+}-elevation is blocked with an IC_{50} value of 3.4 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ophiopogonin D

Cat. No.: HY-N0515

Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C_{29} steroidal glycoside.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Palmitoylglycine

(N-palmitoyl glycine)

Cat. No.: HY-W074890

Palmitoylglycine, a novel endogenous lipid, acts as a modulator of **calcium** influx and **nitric oxide** production in sensory neurons. Palmitoylglycine induces transient influx of calcium followed by nitric oxide production via calcium-sensitive nitric-oxide synthase enzymes.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Palonidipine

Cat. No.: HY-108997

Palonidipine is a **calcium** antagonist which is potential for the therapy of angina-pectoris and hypertension.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Paxilline

Cat. No.: HY-N6778

Paxilline is an indole alkaloid mycotoxin from Penicillium paxilli, acts as a potent **BK channels** inhibitor by an almost exclusively closed-channel block mechanism.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

PD0176078

Cat. No.: HY-U00236

PD0176078 is a newly found N-type **Calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD173212

Cat. No.: HY-103318

PD173212 is a selective **N-type voltage sensitive calcium channel (VSCC)** blocker, with an IC_{50} of 36 nM in IMR-32 assays.



Purity: 98.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

Penfluridol

(R-16341)

Cat. No.: HY-B1077

Penfluridol is a highly potent, first generation diphenylbutylpiperidine antipsychotic.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Pinaverium bromide

Cat. No.: HY-111613

Pinaverium bromide is an L-type **calcium channel** blocker with selectivity for the gastrointestinal tract, effectively relieves pain, diarrhea and intestinal discomfort, provides good therapeutic efficacies without significant adverse effects on Irritable bowel syndrome (IBS) patients.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Pinaverium bromide-d4

Cat. No.: HY-111613S

Pinaverium bromide-d4 is deuterium labeled Pinaverium bromide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Praeruptorin C

Cat. No.: HY-N0079

Praeruptorin C is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a **calcium** antagonist with pD_2' value of 5.7.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Praeruptorin E

Cat. No.: HY-N6066

Praeruptorin E is a main bioactive constituent of Peucedanum praeruptorum (also known as Bai-Hua Qian Hu). Praeruptorin C is a **calcium** antagonist with pD_2' value of 5.2.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pranidipine

(OPC-13340)

Cat. No.: HY-19664

Pranidipine (OPC-13340) is a potent, long acting 1,4-dihydropyridine **calcium channel** blocker with antihypertensive activity.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Propiverine hydrochloride

Cat. No.: HY-116408A

Propiverine hydrochloride is a bladder spasmolytic with calcium antagonistic and anticholinergic properties. Propiverine hydrochloride can be used for the research of overactive blaqdder and urinary incontinence.



Purity: 98.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Propiverine-d7 hydrochloride

Cat. No.: HY-116408AS

Propiverine-d7 hydrochloride is the deuterium labeled Propiverine hydrochloride. Propiverine hydrochloride is a bladder spasmolytic with calcium antagonistic and anticholinergic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ProTx-I

Cat. No.: HY-P1073

ProTx-I, a venom toxin of the tarantula Thrixopelma pruriens, is a potent, selective **$Ca_V3.1$ channel** blocker with **IC_{50}** values of 0.2 μM and 31.8 μM for **$hCa_V3.1$** and **$hCa_V3.2$** respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Psoralenoside

Cat. No.: HY-N7503

Psoralenoside is a benzofuran glycoside from Psoralea corylifolia. Psoralenoside exhibits high binding affinities against **histaminergic H_1**, **calmodulin**, and voltage-gated L-type **calcium channels** (E-value≥-6.5 Kcal/mol).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

R-(-)-Manidipine-d4

Cat. No.: HY-B0419S2

R-(-)-Manidipine-d4 is the deuterium labeled Manidipine. Manidipine is a calcium channel blocker that is used clinically as an antihypertensive.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ranolazine

(CVT 303; RS 43285-003)

Cat. No.: HY-B0280

Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward **sodium** current (I_{Na} and I_{Kr} with IC_{50} values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP).



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Ranolazine dihydrochloride

(CVT 303 dihydrochloride; RS 43285)

Cat. No.: HY-17401

Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward **sodium** current (I_{Na} and I_{Kr} with IC_{50} values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure...



Purity: 99.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Ranolazine-d3

Cat. No.: HY-B0280S2

Ranolazine-d3 is the deuterium labeled Ranolazine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Ranolazine-d5

(CVT 303-d5; RS 43285-003-d5)

Cat. No.: HY-B0280S

Ranolazine-d5 (CVT 303-d5) is the deuterium labeled Ranolazine.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ranolazine-d8

Cat. No.: HY-B0280S1

Ranolazine-d8 (CVT 303-d8) is the deuterium labeled Ranolazine.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Ranolazine-d8 dihydrochloride

(CVT 303-d8 dihydrochloride; RS 43285-d8)

Cat. No.: HY-17401S

Ranolazine-d8 (CVT 303-d8) dihydrochloride is the deuterium labeled Ranolazine dihydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ruthenium red

(Ammoniated ruthenium oxychloride)

Cat. No.: HY-103311

Ruthenium red (Ammoniated ruthenium oxychloride) is a polycationic dye widely used for electron microscopy (EM) of cells, tissues and vegetative bacteria. Ruthenium red strongly reacts with phospholipids and fatty acids and binds to acidic mucopolysaccharides.

Ruthenium red

Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg

S-(+)-Manidipine-d4

Cat. No.: HY-B0419S1

S-(+)-Manidipine-d4 is the deuterium labeled Manidipine. Manidipine is a calcium channel blocker that is used clinically as an antihypertensive.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

SAK3

Cat. No.: HY-120597

SAK3 is a potent T-type voltage-gated Ca^{2+} **channels** (**T-VGCCs**) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type Ca^{2+} channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Semotiadil recemate fumarate

Cat. No.: HY-U00026

Semotiadil recemate fumarate is the recemate of Semotiadil fumarate. Semotiadil fumarate is a novel vasoselective **Ca^{2+} channel** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SERCA2a activator 1

Cat. No.: HY-124873

SERCA2a activator 1 (Compound A) is a **sarco/endoplasmic reticulum Ca^{2+}-dependent ATPase 2a (SERCA2a)** activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

sFTX-3.3

Cat. No.: HY-131942

sFTX-3.3 is a **Ca^{2+} channel** antagonist with **IC_{50}**s of approximately 0.24 mM and 0.70 mM against P-type and N-type channels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sipatrigine

(619C89; BW 619C89)

Cat. No.: HY-108335

Sipatrigine (619C89), a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent **sodium channel** and **calcium channel** inhibitor, penetrating the central nervous system. Has the potential in the study for focal cerebral ischemia and stroke.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SM-6586

Cat. No.: HY-19062

SM-6586 is a **calcium channel** antagonist and inhibitor of Na^+/H^+ and **Na^+/Ca^{2+} exchange transport**, potentially for the treatment of cerebrovasular diseases and hypertension.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNX-482

Cat. No.: HY-P1074

SNX-482, a peptidyl toxin of the spider Hysterocrates gigas, is a potent, high affinity, selective and voltage-dependent R-type **$Ca_V2.3$ channel** blocker with an **IC_{50}** of 30 nM. SNX-482 has antinociceptive effect.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SQ-31765

(SQ31765; SQ 31765)

Cat. No.: HY-101740

SQ-31765 is a benzazepine **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR33805

Cat. No.: HY-136909

SR33805 is a potent **Ca^{2+} channel** antagonist, with **EC_{50}**s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca^{2+} channels. SR33805 can be used for the research of acute or chronic failing hearts.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Suvecaltamide

(MK-8998)

Cat. No.: HY-101096

Suvecaltamide (MK-8998; compound 33) is a potent and selective inhibitor of the T-type **calcium channel**.



Purity: 99.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Syntide 2

Cat. No.: HY-P0271

Syntide 2, a **Ca^{2+}**- and **calmodulin (CaM)-dependent protein kinase II (CaMKII)** substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected.

PLARTLSVAGLPGKK

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Syntide 2 TFA

Cat. No.: HY-P0271A

Syntide 2 (TFA), a Ca^{2+}- and **calmodulin (CaM)-dependent protein kinase II (CaMKII)** substrate peptide, selectively inhibits the gibberellin (GA) response, leaving constitutive and abscisic acid-regulated events unaffected.

PLARTLSVAGLPGKK (TFA salt)

Purity: 99.26%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Taurolithocholic acid sodium salt

Cat. No.: HY-113308A

Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca^{2+} agonist.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Taurolithocholic acid-d4

Cat. No.: HY-113308S1

Taurolithocholic acid-d4 is deuterium labeled Taurolithocholic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taurolithocholic acid-d4 sodium

Cat. No.: HY-113308AS

Taurolithocholic acid-d4 sodium is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca^{2+} agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taurolithocholic acid-d4-1 sodium

Cat. No.: HY-113308AS2

Taurolithocholic acid-d4-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca2+ agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taurolithocholic acid-d5

Cat. No.: HY-113308S

Taurolithocholic acid-d5 is deuterium labeled Taurolithocholic acid.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Taurolithocholic Acid-d5 sodium salt

Cat. No.: HY-113308AS1

Taurolithocholic Acid-d5 sodium salt is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic acid sodium salt, a potent cholestatic agent, is a potent Ca^{2+} agonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

TDN345

Cat. No.: HY-101669

TDN345 is a Ca^{2+} antagonist, used for the treatment of vascular and senile dementia including Alzheimer's disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Teludipine hydrochloride

(GR53992B; GX1296B)

Cat. No.: HY-101621

Teludipine is a lipophilic **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Teludipine-d6

Cat. No.: HY-101621S

Teludipine-d6 (GR53992B-d6) is the deuterium labeled Teludipine hydrochloride. Teludipine is a lipophilic **calcium channel** blocker.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

Terodiline

Cat. No.: HY-16489

Terodiline is an **M1**-selective **muscarinic receptor (mAChR)** antagonist with K_bs of 15, 160, 280, and 198 nM in rabbit vas deferens (M1), atria (M2), bladder (M3) and ileal muscle (M3), respectively. Terodiline also is a **Ca^{2+}** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Terodiline hydrochloride

Cat. No.: HY-16489A

Terodiline hydrochloride is an **M1**-selective **muscarinic receptor (mAChR)** antagonist with K_bs of 15, 160, 280, and 198 nM in rabbit vas deferens (M1), atria (M2), bladder (M3) and ileal muscle (M3), respectively. Terodiline hydrochloride also is a **Ca^{2+}** blocker.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 5 mg

Tetrandrine

(NSC-77037; d-Tetrandrine)

Cat. No.: HY-13764

Tetrandrine (NSC-77037; d-Tetrandrine) is a bis-benzyl-isoquinoline alkaloid, which inhibits voltage-gated **Ca^{2+} current** (ICa) and Ca^{2+}-activated **K^+ current**.



Purity: 99.90%
Clinical Data: Launched
Size: 100 mg, 250 mg

Thapsigargin

Cat. No.: HY-13433

Thapsigargin, an **endoplasmic reticulum (ER) stress** inducer, is an inhibitor of microsomal **Ca^{2+}-ATPase**. Thapsigargin efficiently inhibits coronavirus (HCoV-229E, MERS-CoV, SARS-CoV-2) replication in different cell types.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Tiapamil hydrochloride

(Ro 11-1781)

Cat. No.: HY-101674

Tiapamil hydrochloride is a **calcium channel** blocker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Topiramate

(McN 4853; RWJ 17021)

Cat. No.: HY-B0122

Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a **GluR5 receptor** antagonist.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Topiramate D12

(McN 4853 D12 ; RWJ 17021 D12)

Cat. No.: HY-110234

Topiramate D12 (McN 4853 D12) is a deuterium labeled Topiramate. Topiramate is a broad-spectrum antiepileptic agent. Topiramate is a **GluR5 receptor** antagonist.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

TPC2-A1-N

Cat. No.: HY-131614

TPC2-A1-N is a powerful and Ca^{2+}-permeable agonist of **two pore channel 2 (TPC2)**, which plays its role by mimicking the physiological actions of NAADP.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

trans-Ned 19

Cat. No.: HY-103316

trans-Ned 19, a **NAADP** antagonist and **TPC** blocker, suppresses the **calcium signal** in human umbilical vein endothelial cells (HUVEC) and the rat aorta relaxation in response to low histamine concentrations.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Trimethadione

(3,5,5,-Trimethyloxazolidine-2,4-dione)

Cat. No.: HY-A0092

Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type **calcium channel** blocker which has antihyperalgesic effects.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

TTA-A2

Cat. No.: HY-111828

TTA-A2 is a potent, selective and orally active **t-type voltage gated calcium channel** antagonist with reduced pregnane X receptor (PXR) activation.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TTA-P1

Cat. No.: HY-10955

TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TTA-P2

(T-Type calcium channel inhibitor)

Cat. No.: HY-10035

TTA-P2 (T-Type calcium channel inhibitor) is a potent inhibitor of T-Type calcium channel.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TTA-Q6

Cat. No.: HY-10388

TTA-Q6 is a selective **T-type Ca^{2+} channel** antagonist, which can be used in the research of neurological disease.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

UK-59811 hydrochloride

Cat. No.: HY-136189

UK-59811 hydrochloride, a Br-dihydropyridine derivative, is a potent bacterial homotetrameric model voltage-gated Ca^{2+} (Ca_V) channel **Ca_VAb** inhibitor with an **IC_{50}** of 194 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UK51656

Cat. No.: HY-101707

UK51656 is a **calcium** antagonist with **IC_{50}** of 4 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Urolithin C

Cat. No.: HY-135897

Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of **insulin secretion**. Urolithin C is a **L-type Ca^{2+} channel** opener and enhances **Ca^{2+}** influx.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Verapamil

((±)-Verapamil; CP-16533-1)

Cat. No.: HY-14275

Verapamil ((±)-Verapamil) is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor. Verapamil also inhibits **CYP3A4**. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research.



Purity: 99.96%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 50 mg

Verapamil EP Impurity C hydrochloride

(NSC-609249 hydrochloride)

Cat. No.: HY-136589

NSC-609249 hydrochloride is an **impurity** of Verapamil (HY-14275). Verapamil is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Verapamil hydrochloride

((±)-Verapamil hydrochloride; CP-16533-1 hydrochloride)

Cat. No.: HY-A0064

Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor. Verapamil hydrochloride also inhibits **CYP3A4**.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Verapamil-d3 hydrochloride ((±)-Verapamil-d3 hydrochloride; CP-16533-1-d3 hydrochloride)

Cat. No.: HY-A0064S

Verapamil-d3 ((±)-Verapamil-d3) hydrochloride is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a **calcium channel** blocker and a potent and orally active first-generation **P-glycoprotein (P-gp)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VK-II-36

Cat. No.: HY-111014

VK-II-36 is a carvedilol analog that suppresses sarcoplasmic reticulum Ca^{2+}release but does not block the β-receptor.VK-II-36 inhibits triggered activities evoked by both early and delayed after depolarizations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Xestospongin C ((-)-Xestospongin C)

Cat. No.: HY-103312

Xestospongin C ((-)-Xestospongin C) is a selective, reversible **inositol 1,4,5-trisphosphate receptor (IP3R)** inhibitor. Xestospongin C acts as an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca^{2+} ATPase (SERCA) pump of internal stores.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 μg, 25 μg

Yangambin

Cat. No.: HY-N4267

Yangambin, a furofuran lignan, is already isolated from plants such as member of the Annonaceae family, including species of the genus Rollinia: R. pickeli, R. exalbidaand R. mucosa, as well from the Magnolia biondii.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

YS-201

Cat. No.: HY-U00137

YS-201 is a dihydropyridine-type **calcium channel** antagonist. YS-201 has the potential for angina pectoris and hypertension treatment.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg

Z944

Cat. No.: HY-120546

Z944 is a **T-type calcium channel** antagonist that rescues impairments in crossmodal and visual recognition memory.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ziconotide (SNX-111)

Cat. No.: HY-P0062

Ziconotide (SNX-111), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ziconotide acetate (SNX-111 acetate)

Cat. No.: HY-P0062B

Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research.



Purity: 99.64%
Clinical Data: Launched
Size: 5 mg, 10 mg

Ziconotide TFA (SNX-111 TFA)

Cat. No.: HY-P0062A

Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Zonisamide (AD 810; CI 912)

Cat. No.: HY-B0124

Zonisamide (AD 810) is an inhibitor of zinc enzyme **carbonic anhydrase (CA)**, with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Zonisamide sodium

(AD 810 sodium; CI 912 sodium)

Cat. No.: HY-B0124A

Zonisamide sodium (AD 810 sodium) is an inhibitor of zinc enzyme **carbonic anhydrase (CA)**, with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide sodium has antiepileptic activity.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Zonisamide-d4

Cat. No.: HY-B0124S

Zonisamide-d4 (AD 810-d4) is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme **carbonic anhydrase (CA)**, with K_is of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity.



Purity: >98%
Clinical Data:
Size: 500 µg, 5 mg

ZSET1446

(ST-101)

Cat. No.: HY-11013

ZSET1446 is a novel cognitive enhancer that significantly improves learning deficits in various types of Alzheimer disease (AD) models.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

β-Amino Acid Imagabalin Hydrochloride

(PD-0332334)

Cat. No.: HY-U00250

β-Amino Acid Imagabalin Hydrochloride (PD-0332334) is a ligand for the α2δ subunit of the voltage-dependent **calcium channel**.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

β-Cyfluthrin

(beta-Cyfluthrin)

Cat. No.: HY-B1837A

β-Cyfluthrin (beta-Cyfluthrin) is a type II synthetic **pyrethroid** and also an active ingredient of many insecticide products used for pestsin agriculture.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

ω-Agatoxin IVA

Cat. No.: HY-P1080

ω-Agatoxin IVA is a potent, selective **P/Q type Ca^{2+} (Cav2.1) channel** blocker with IC_{50}s of 2 nM and 90 nM for **P-type** and **Q-type Ca^{2+} channels**, respectively. ω-Agatoxin IVA (IC_{50}, 30-225 nM) inhibits glutamate exocytosis and calcium influx elicited by high potassium.

OMEGA-Agatoxin IVA

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ω-Agatoxin TK

Cat. No.: HY-P1079

ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective **P/Q type Ca^{2+} channel** blocker. ω-Agatoxin TK inhibits the high K^+ depolarisation-induced rise in internal Ca^{2+} in cerebral isolated nerve endings with an IC_{50} of of 60 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ω-Conotoxin GVIA

Cat. No.: HY-P0189

ω-Conotoxin GVIA is an inhibitor of the N-type **Ca^{2+} channel**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ω-Conotoxin GVIA TFA

Cat. No.: HY-P0189A

ω-Conotoxin GVIA TFA is an inhibitor of the N-type **Ca^{2+} channel**.

Purity: 99.03%
Clinical Data: No Development Reported
Size: 1 mg

ω-Conotoxin MVIIC

Cat. No.: HY-P0188

ω-Conotoxin MVIIC is a N- and P/Q-type **Ca^{2+} channel** blocker, significantly suppresses the 11-keto-βboswellic acid-mediated inhibition of glutamate release.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ω-Conotoxin MVIIC TFA

Cat. No.: HY-P0188A

ω-Conotoxin MVIIC TFA is a N- and P/Q-type Ca^{2+} **channel** blocker, significantly suppresses the 11-keto-βboswellic acid-mediated inhibition of glutamate release.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg